tiprankstipranks
Resmed (RMD)
NYSE:RMD
Holding RMD?
Track your performance easily

Resmed (RMD) Stock Forecast & Price Target

997 Followers
See the Price Targets and Ratings of:

RMD Analyst Ratings

Moderate Buy
11Ratings
6 Buy
4 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$247.14
▲(1.38% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $247.14 with a high forecast of $283.00 and a low forecast of $180.00. The average price target represents a 1.38% change from the last price of $243.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"151":"$151","284":"$284","184.25":"$184.3","217.5":"$217.5","250.75":"$250.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":283,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$283.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$247.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$180.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[151,184.25,217.5,250.75,284],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.75,246.76923076923077,249.78846153846155,252.80769230769232,255.82692307692307,258.84615384615387,261.86538461538464,264.88461538461536,267.90384615384613,270.9230769230769,273.9423076923077,276.96153846153845,279.9807692307692,{"y":283,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.75,244.01076923076923,244.27153846153846,244.53230769230768,244.7930769230769,245.05384615384614,245.31461538461537,245.57538461538462,245.83615384615385,246.09692307692308,246.3576923076923,246.61846153846153,246.87923076923076,{"y":247.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.75,238.84615384615384,233.94230769230768,229.03846153846155,224.1346153846154,219.23076923076923,214.32692307692307,209.4230769230769,204.51923076923077,199.6153846153846,194.71153846153845,189.80769230769232,184.90384615384613,{"y":180,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.46,"date":1700784000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.16,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.28,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.08,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.43,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.49,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.52,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.95,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.86,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.62,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.34,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.48,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$283.00Average Price Target$247.14Lowest Price Target$180.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair
Buy
Reiterated
08/27/24
ResMed sees 'tidal wave' from weight loss drugs, says William BlairResMed sees 'tidal wave' from weight loss drugs, says William Blair
UBS
$210$225
Hold
-7.70%
Downside
Reiterated
08/05/24
ResMed (RMD) PT Raised to $225 at UBSUBS analyst Laura Sutcliffe raised the price target on ResMed (NYSE: RMD) to $225.00 (from $210.00) while maintaining a Neutral rating.
Citi
Buy
Reiterated
06/24/24
Australian Stocks: ResMed Shares Tumble on Rivals Weight-Loss Drug Results - TipRanks.comDespite investors concerns over ResMeds future sales, analysts remain positive. After the shares dipped today, analyst Mathieu Chevrier from Citi reiterated a Buy rating on RMD stock, predicting an upside of 28.5%.

Best Analysts Covering Resmed

Which Analyst Should I Follow If I Want to Buy RMD and Sell After:
1 Month
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+3.53%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +3.53% per trade.
3 Months
xxx
Success Rate
14/19 ratings generated profit
74%
Average Return
+6.43%
assigned a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +6.43% per trade.
1 Year
Lyanne HarrisonBank of America Securities
Success Rate
13/19 ratings generated profit
68%
Average Return
+14.75%
assigned a buy rating 19 days ago
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +14.75% per trade.
2 Years
xxx
Success Rate
17/19 ratings generated profit
89%
Average Return
+21.31%
assigned a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +21.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
0
0
0
0
0
Buy
13
11
11
19
14
Hold
4
6
7
13
9
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
17
17
19
33
24
In the current month, RMD has received 14 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. RMD average Analyst price target in the past 3 months is $247.14.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.32 with a range of $2.26 to $2.44. The previous quarter’s EPS was $2.20. RMD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.93% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s earnings estimate for RMD is $2.32 with a range of $2.26 to $2.44. The previous quarter’s EPS was $2.20. RMD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.93% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.27B with a range of $1.25B to $1.30B. The previous quarter’s sales results were $1.22B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.69% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s sales forecast for RMD is $1.27B with a range of $1.25B to $1.30B. The previous quarter’s sales results were $1.22B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.69% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is $247.14.
    What is RMD’s upside potential, based on the analysts’ average price target?
    Resmed has 1.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RMD a Buy, Sell or Hold?
          Resmed has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Resmed’s price target?
            The average price target for Resmed is $247.14. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $283.00 ,the lowest forecast is $180.00. The average price target represents 1.38% Increase from the current price of $243.78.
              What do analysts say about Resmed?
              Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of RMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis